Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lefamulin (Primary) ; Lefamulin (Primary) ; Linezolid; Linezolid; Moxifloxacin; Moxifloxacin
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms LEAP; LEAP 1
  • Sponsors Nabriva Therapeutics
  • Most Recent Events

    • 15 Oct 2019 According to a Nabriva Therapeutics media release, pooled results from completed pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 clinical trials will be featured in three e-poster presentations during a moderated grand-rounds session at the CHEST Annual Meeting 2019 (October 19-23 in New Orleans).
    • 19 Aug 2019 Pooled data from LEAP 1 and LEAP 2 published in the Nabriva Therapeutics Media Release.
    • 19 Aug 2019 According to an Nabriva Therapeutics media release, the company announced that the U.S. Food and Drug Administration (FDA) has approved new drug applications for the oral and intravenous (IV) formulations of Xenleta™ (lefamulin) for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top